CATABASIS PHARMACEUTICALS IN's ticker is CATB and the CUSIP is 14875P107. A total of 23 filers reported holding CATABASIS PHARMACEUTICALS IN in Q1 2017. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2017 | $441,000 | -11.3% | 310,756 | 0.0% | 0.06% | -20.3% |
| Q1 2017 | $497,000 | +37.7% | 310,756 | +210.8% | 0.08% | +14.5% |
| Q4 2016 | $361,000 | -99.9% | 100,000 | 0.0% | 0.07% | -29.6% |
| Q3 2016 | $616,000,000 | +48138.1% | 100,000 | -71.0% | 0.10% | -56.8% |
| Q2 2016 | $1,277,000 | -26.6% | 345,100 | 0.0% | 0.23% | -34.2% |
| Q1 2016 | $1,739,000 | -28.4% | 345,100 | +12.7% | 0.34% | -6.0% |
| Q4 2015 | $2,428,000 | -0.1% | 306,227 | +1.9% | 0.37% | -5.2% |
| Q3 2015 | $2,430,000 | -25.0% | 300,427 | +13.2% | 0.39% | -0.5% |
| Q2 2015 | $3,241,000 | – | 265,427 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SV Health Investors, LLC | 2,857,667 | $23,118,000 | 12.93% |
| Clarus Ventures, LLC | 2,752,488 | $22,268,000 | 12.81% |
| Camber Capital Management LP | 1,000,000 | $8,090,000 | 0.69% |
| Rhenman & Partners Asset Management AB | 300,427 | $2,430,000 | 0.39% |
| SPHERA FUNDS MANAGEMENT LTD. | 327,476 | $2,595,000 | 0.33% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 628,482 | $5,084,000 | 0.20% |
| Spark Investment Management LLC | 32,500 | $263,000 | 0.03% |
| Tower Research Capital LLC (TRC) | 10,764 | $87,000 | 0.01% |
| VANGUARD GROUP INC | 4,732,472 | $168,937,000 | 0.01% |
| Alyeska Investment Group, L.P. | 40,220 | $325,000 | 0.00% |